Advertisement

Current Psychiatry Reports

, Volume 9, Issue 5, pp 358–364 | Cite as

Why buprenorphine is so successful in treating opiate addiction in France

  • M. Fatseas
  • Marc AuriacombeEmail author
Article

Abstract

In France, all registered medical doctors have been allowed to prescribe buprenorphine without any special education or licensing since 1995. This has led to a rapidly increasing number of opiate-dependent users under buprenorphine treatment in primary care. French physician compensation mechanisms, pharmacy services, and medical insurance funding all have contributed to minimizing barriers to buprenorphine treatment. Approximately 20% of all physicians in France are prescribing buprenorphine to treat more than one half of the estimated 180,000 problem heroin users. Intravenous diversion of buprenorphine may occur in up to 20% of buprenorphine patients and has led to relatively rare overdoses in combination with sedatives, whereas total opiate overdose deaths have declined substantially. In France, buprenorphine maintenance treatment for problem opiate users was feasible and safe through office-based prescriptions in a relaxed regulatory environment.

Keywords

Heroin Methadone Treatment Overdose Death Opiate Dependence Opiate Addiction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Farrell M, Howes S, Verster A, et al., eds.: Reviewing Current Practice in Drug Substitution Treatment in the European Union. Luxembourg: Office for Official Publications of the European Communities; 2000.Google Scholar
  2. 2.
    EMCDDA: Annual Report on the State of the Drug Problem in the European Union and Norway. Luxembourg: Office for Official Publications of the European Communities; 2002.Google Scholar
  3. 3.
    Haasen C, Stallwitz A, Lachmann A, et al.: Management of High Risk Opiate Addicts in Europe (Risk Opiate Addicts Study — Europe) — Final Report. Hamburg, Germany: Centre for Interdisciplinary Addiction Research, University of Hamburg; 2004.Google Scholar
  4. 4.
    EMCDDA: Annual Report 2000: The State of the Drug Problem in the European Union and Norway. Lisbon: EMCDDA; 2000.Google Scholar
  5. 5.
    EMCDDA: Annual Report 2005: The State of the Drug Problem in the European Union and Norway, issue 3: Buprenorphine-Treatment, Misuse and Prescription Practices. Lisbon: EMCDDA; 2005.Google Scholar
  6. 6.
    Auriacombe M, Grabot D, Daulouède JP, et al.: Alternatives to methadone maintenance: laudanum, buprenorphine. In 54th Annual Scientific Meeting, College on Problems of Drug Dependence. Edited by Harris H. Keystone, CO: NIDA Research Monograph; 1992:308.Google Scholar
  7. 7.
    Auriacombe M, Grabot D, Daulouede JP, et al.: A naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: effect on biopsychosocial status. J Subst Abuse Treat 1994, 11:565–568.PubMedCrossRefGoogle Scholar
  8. 8.
    Auriacombe M, Fatseas M, Dubernet J, et al.: French field experience with buprenorphine. Am J Addict 2004, 13(Suppl 1):S17–S28.PubMedCrossRefGoogle Scholar
  9. 9.
    Auriacombe M: Overview on substitution treatment for heroin users in France. In Reviewing Current Practice in Drug Substitution Treatment in the European Union. Edited by Farrell M, Howes S, Verster A, et al.: Luxembourg: Office for Official Publications of the European Communities; 2000:119–134.Google Scholar
  10. 10.
    Obser vatoire Français des Drogues et des Toxicomanies: Les Traitements de Substitution en France: Résultats Récents 2004. Paris: Tendances; 2004:8.Google Scholar
  11. 11.
    Cadet-Taïrou A, Chollet D: La Substitution à Travers 13 Sites Français, 1999–2002. Pratiques et Disparités Régionales. Paris: CNAMTS/OFDT; 2004.Google Scholar
  12. 12.
    Feroni I, Paraponaris A, Aubisson S, et al.: Prescription de buprenorphine haut dosage par des médecins generalists. Rev Epidemiol Sante Publique 2004, 52:511–522.PubMedGoogle Scholar
  13. 13.
    Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994, 151:1025–1030.PubMedGoogle Scholar
  14. 14.
    Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003, 2:CD002207.Google Scholar
  15. 15.
    Cowan A, Lewis JW. Buprenorphine. New York: Wiley-Liss; 1995.Google Scholar
  16. 16.
    Fielding JE, Lancry PJ. Lessons from France—’vive la difference.’ The French health care system and US health system reform. JAMA 1993, 270:748–756.PubMedCrossRefGoogle Scholar
  17. 17.
    Kopp P, Rumeau-Pichon C, Le Pen C: Les enjeux financiers des traitements de substitution dans l’heroinomanie: le cas de Subutex. Rev Epidemiol Sante Publique 2000, 48:256–270.PubMedGoogle Scholar
  18. 18.
    Fédération Française d’addictologie: Stratégies thérapeutiques pour les personnes dépendantes des opiacés: place des traitements de substitution. Conférence de Consensus, 2004. Lyon, France; June 23–24, 2004.Google Scholar
  19. 19.
    Bilal S, Menares J, De La Selle P, et al.: Impact des traitements de substitution aux opiacés sur la vie sociale. Une etude en medecine de ville. Ann Med Interne (Paris) 2003, 154(Suppl 2):S6–S14.Google Scholar
  20. 20.
    Duburcq A, Charpak Y, Blin P, Madec L: Suivi a 2 ans d’une cohorte de patients sous buprenorphine haut dosage. Resultats de l’etude SPESUB (suivi pharmaco-epidemiologique du Subutex en medecine de ville). Rev Epidemiol Sante Publique 2000, 48:363–373.PubMedGoogle Scholar
  21. 21.
    Auriacombe M, Poutet R, Lavis E, et al.: Change in i.v. sharing behavior and condom use among admissions to opiate dependence treatment over a 10-year period (1994–2003). The College on Problems of Drug Dependence 67th Annual Scientific Meeting, 2005. Orlando, FL; June 19–23, 2005.Google Scholar
  22. 22.
    De Ducla M, Gagnon A, Mucchielli A, et al.: Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks. Ann Med Interne (Paris) 2000, 151(Suppl B):B9–B15.Google Scholar
  23. 23.
    De Ducla M, Gagnon A, Mucchielli A, et al.: Suivi de patients pharmacodependants aux opiaces traites par buprenorphine haut dosage a partir de reseaux de soins. Etude retrospective nationale. Experience de medecins generalistes francais. Ann Med Interne (Paris) 2000, 151(Suppl A):A27–A32.Google Scholar
  24. 24.
    Fhima A, Henrion R, Lowenstein W, Charpak Y: Suivi a 2 ans d’une cohorte de patients dependants aux opiaces traites par buprenorphine haut dosage (Subutex). Ann Med Interne (Paris) 2001, 152(Suppl 3):IS26–IS36.Google Scholar
  25. 25.
    Office Central Pour la Répression du Trafic Illicite des Stupéfiants: Usage et Trafic de Drogues en France. Les Statistiques de l’année 1998. Paris: Ministère de l’Intérieur; 1999.Google Scholar
  26. 26.
    Auriacombe M, Franques P, Tignol J: Deaths attributable to methadone vs buprenorphine in France. JAMA 2001, 285:45.PubMedCrossRefGoogle Scholar
  27. 27.
    Lepere B, Gourarier L, Sanchez M, et al.: Diminution du nombre de surdoses mortelles a l’heroine, en France, depuis 1994. A propos du role des traitements de substitution. Ann Med Interne (Paris) 2001, 152(Suppl 3):IS5–IS12.Google Scholar
  28. 28.
    Emmanuelli J, Desenclos JC: Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 2005, 100:1690–1700.PubMedCrossRefGoogle Scholar
  29. 29.
    Soyka M, Apelt SM, Lieb M, Wittchen HU: One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006, 26:657–660.PubMedCrossRefGoogle Scholar
  30. 30.
    Soyka M, Penning R, Wittchen U: Fatal poisoning in methadone and buprenorphine treated patients — are there differences? Pharmacopsychiatry 2006, 39:85–87.PubMedCrossRefGoogle Scholar
  31. 31.
    Kintz P: Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001, 121:65–69.PubMedCrossRefGoogle Scholar
  32. 32.
    Reynaud M, Petit G, Potard D, Courty P: Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998, 93:1385–1392.PubMedCrossRefGoogle Scholar
  33. 33.
    Reynaud M, Tracqui A, Petit G, et al.: Six deaths linked to misuse of buprenorphine-benzodiazepine combinations [letter]. Am J Psychiatry 1998, 155:448–449.PubMedGoogle Scholar
  34. 34.
    Tracqui A, Kintz P, Ludes B: In buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998, 22:430–434.PubMedGoogle Scholar
  35. 35.
    Tracqui A, Reynaud M, Petit G, et al.: Danger de l’utilisation détournée d’une association Benzodiazepines-buprenorphine. Sysnapse 1997, 133:41–46.Google Scholar
  36. 36.
    Observatoire Français des Drogues et des Toxicomanies: Rapport National Pour l’EMCDDA. Nouveaux Développements et Tendances, Conséquences Sanitaires. Paris: OFDT; 2005.Google Scholar
  37. 37.
    Damon M, Claroux-Bellocq D, Degré A: Substitution par la buprénorphine en médecine de ville, en Aquitaine. Revue Médicale de l’assurance Maladie 2001, 32:311–318.Google Scholar
  38. 38.
    Thirion X, Lapierre V, Micallef J, et al.: Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002, 65:197–204.PubMedCrossRefGoogle Scholar
  39. 39.
    Vignau J, Duhamel A, Catteau J, et al.: Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients? J Subst Abuse Treat 2001, 21:135–144.PubMedCrossRefGoogle Scholar
  40. 40.
    Feroni I, Peretti-Watel P, Paraponaris A, et al.: French general practitioners’ attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse? J Addict Dis 2005, 24:7–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Carrieri MP, Amass L, Lucas GM, et al.: Buprenorphine use: the international experience. Clin Infect Dis 2006, 43(Suppl 4):S197–S215.PubMedCrossRefGoogle Scholar
  42. 42.
    Blanchon T, Boissonnas A, Vareseon I, Vidal-Trecan G: Homelessness and high-dosage buprenorphine misuse. Subst Use Misuse 2003, 38:429–442.PubMedCrossRefGoogle Scholar
  43. 43.
    Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A: Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003, 69:175–181.PubMedCrossRefGoogle Scholar
  44. 44.
    Thirion X, Micallef J, Barrau K, et al.: Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur Addict Res 2001, 7:32–36.PubMedCrossRefGoogle Scholar
  45. 45.
    Thirion X, Micallef J, Guet F, et al.: Dependance aux psychotropes et traitements de substitution: tendances recentes a propos de l’enquete OPPIDUM des Centres d’Evaluation et d’Information sur les Pharmacodependances (CEIP) d’octobre 1997. Therapie 1999, 54:243–249.PubMedGoogle Scholar
  46. 46.
    Moatti JP, Vlahov D, Feroni I, et al.: Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. Eur Addict Res 2001, 7:40–45.PubMedCrossRefGoogle Scholar
  47. 47.
    Obadia Y, Perrin V, Feroni I, et al.: Injecting misuse of buprenorphine among French drug users. Addiction 2001, 96:267–272.PubMedCrossRefGoogle Scholar
  48. 48.
    Valenciano M, Emmanuelli J, Lert F: Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction 2001, 96:597–606.PubMedCrossRefGoogle Scholar
  49. 49.
    Fontaa V, Bronner C: Persistance de la pratique d’injection chez des patients substitues par methadone ou buprenorphine haut dosage. Ann Med Interne (Paris) 2001, 152(Suppl 7):59–69.Google Scholar
  50. 50.
    Franques P, Lavie E, Encrenaz G, et al.: Facteurs d’évolution du comportement de dépendance sous traitement par buprénorphine: mésusage de la buprénorphine par voie veineuse en situation de traitement. Importance du phénomène et caractéristiques des sujets. Résultats préliminaires à partir d’une étude en cours. Courrier des Addictions 2003, 5:14–18.Google Scholar
  51. 51.
    Escot S, Fahet G: Usages non Substitutifs de la Buprénorphine Haut Dosage Menée en France, en 2002–2003. Paris: OFDT; 2004.Google Scholar
  52. 52.
    Auriacombe M, Franques P, Daulouède J, et al.: Traitements de substitution: le médicament est. celui qui le donne. Les modalités de mise à disposition d’un traitement de substitution par buprénorphine influencent-elles la réponse générale au traitement? Courrier des Addictions 2002, 4:104–106.Google Scholar
  53. 53.
    ANAES: Evaluation des Réseaux de Soins: Bilan de l’existant et Cadre Méthodologique. Paris: ANAES; 2001.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Département d’AddictologieCentre CarreireBordeaux CedexFrance

Personalised recommendations